Foghorn Therapeutics (FHTX) Other financing activities (2024 - 2026)
Foghorn Therapeutics (FHTX) recorded quarterly Other financing activities of $316000.0 in Q1 2026, down 18.97% quarter-over-quarter from $390000.0 in Q3 2024.
Foghorn Therapeutics (FHTX) Other financing activities (2024 - 2026) Analysis & Trends
Foghorn Therapeutics' Other financing activities history runs 2 years deep, the most recent figure standing at $316000.0 for Q1 2026.
- In Q1 2026, Other financing activities changed N/A year-over-year to $316000.0; the TTM figure through Mar 2026 stood at $316000.0 (down 18.97% YoY), while the FY2024 annual figure was $585000.0, changed N/A from the prior year.
- Other financing activities was $316000.0 for Q1 2026 at Foghorn Therapeutics, down from $390000.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $390000.0 in Q3 2024 to a low of $316000.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Foghorn Therapeutics | 282.33 Mn | 193.42 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 316,000.00 |
| Mar 31, 2026 | 316,000.00 |
| Sep 30, 2024 | 390,000.00 |
| Sep 30, 2024 | 390,000.00 |